MOLECULAR REGULATION OF PLATELET PRODUCTION

血栓生成素是唯一与生理相关的造血生长 调节血小板生成的因子。因为它被确认为 三年前，原创公司进行了广泛的研究， 主要以工业为基础的实验室，以努力了解其 作用机制。这些信息中的大部分已在 血小板生成素与细胞因子调控会议 血小板生产于1996年2月举行。在过去几年里 一大批新的学术和产业调查人员进入 这一领域极大地扩展了基础科学研究的范围 促血小板生成素的研究。此外，临床的发展 这一领域的研究进展如此之快，以至于大量研究 即将被报道..因此，这个基石的目的是 血小板生成的分子调控研讨会即将召开 聚集这一领域的学术界和产业界研究人员讨论 这一快速发展领域的最新基础和临床发现。 鉴于预期一个或多个重组血小板生成素 分子将在明年内获得FDA的批准，时间 这次聚会的重要性至关重要。这次研讨会将允许新的临床 和基础科学研究人员一起交流他们的研究成果 当血小板生成素的临床应用正在发展的时候。 血小板生成素的使用指南将会出现，这将确保 这些分子在临床上使用的基本原理。青年调查员 学员将有机会接触到最新的临床和基础知识 用来制定他们自己的实验的信息。已建立 临床医生和基础科学家将有一个独特的机会 综合当前信息，指导……进一步发展 促血小板生成素。提供足够的资源来资助这项工作 研讨会将保证公平地平衡 学术和工业研究人员以及 以学术为基础的博士后和研究生参加。

Thrombpoietin ia the only physiological relevant hematopoietic growth factor that regulates platelet production. Since its identification three years ago, extensive research was undertaken by the original, primarily industrial-based, laboratories in an effort to understand its mechanism of action. Much of this information was summarized at the Keystone Conference on Thrombopoietin and Cytokine Regulation of Platelet Production held in February of 1996. In the past several years a large number of new academic and industrial investigators have entered this field and have greatly extended the scope of basic scientific investigation on thrombopoietin. In addition, the clinical development of this area is progressing so rapidly that a large number of studies are about to be reported..It is therefore the purpose of this Keystone Symposium on Molecular Regulation of Platelet Production to bring together the academic and industrial researchers in this area to discuss the recent basic and clinical findings in this rapidly progressing area. Given the expectation that one or more of the recombinant thrombopoietin molecules will be approved by the FDA within the next year, The timing of this gathering is crucial. This symposium will allow new clinical and basic science investigators to exchange their findings at a time when the clinical applications of thrombopoietin are being developed. Guidelines for the use of thrombopoietin will emerge which will ensure the rationale use of these molecules in the clinic. Young investigators and trainees will have access to the most recent clinical and basic information with which to formulate their own experiments. Established clinicians and basic scientists will have a unique opportunity to synthesize current information and guide the further development of thrombopoietin. The provision of adequate resources to fund this symposium will guarantee an equitable balance of viewpoint between academic and industrial researchers as well as the opportunity for academically-based post-doctoral and graduate students to participate.